Synopsis
Process Development is the application of chemistry to the scale up of new synthetic processes from the laboratory, through pilot plant to full scale commercial manufacture and into life cycle management. It is an extremely broad discipline, crossing the boundaries between synthetic organic chemistry, process technology and chemical engineering.
The area of Process Development continues to be a challenging and important area for the research into and application of modern synthetic organic chemistry, as well as enabling technologies.
Attendees
The symposium aims to bring together a wide range of speakers from across the Pharmaceutical, Agrochemical and Fine Chemical industries, as well as from an academic background. This meeting brings together experts from across the entire spectrum of the discipline to present state of the art process development.
Sponsorship and Exhibition
For further information and prices, please email conferences@soci.org.
Accommodation
Accommodation is now sold out
Programme
Wednesday 10 April
- 11.00
- Registration and refreshments
- 12.15
- Lunch and exhibition
CHAIRPERSON: David Lathbury, Astute chemical development consulting Ltd, UK
- 13.25
- Opening remarks
- 13.30
- The largest small molecule: How chemistry enabled the discovery and development of PCSK9 inhibitor MK-0616
Dr David Thaisrivongs, MSD, USA
- 14.10
- A reluctant process chemist – A review of key projects in a 35-year career
Dr Ian Lennon, Chiralquest, UK
- 14.50
- From early phase to full scale manufacturing. An overview of biocatalysis at Novartis pharma
Thierry Schlama, Novartis Basel, Switzerland
- 15.30
- Refreshment break and exhibition
CHAIRPERSON: Max Espensen, Pharmaron, UK
- 16.10
- Adventures in the development of complex pharmaceuticals
Dr Francisco Gonzalez Bobes, Bristol-Myers Squibb, USA
- 16.50
- Development of a large-scale photoredox fluorodecarboxylation of aliphatic carboxylic acids
Dr Aaron Dumas, Pharmaron Hoddesdon, UK
- 17.20
- Closing remarks
- 17.30
- Wine reception sponsored by ChiralQuest (until 18.15)
- 19.00
- Dinner for residents of the college
Thursday 11 April
CHAIRPERSON: Hilmar Weinmann, Johnson & Johnson Innovative Medicine, Belgium
- 09:00
- Minimizing hazards and risks in chemical process development: Structure-related reactivity investigation of five-membered cyclic sulfamidates
Dr Michael Parmentier, Novartis, Switzerland
- 09.40
- The impact of bringing development capabilities into discovery phase in finding long-acting RSV PreP inhibitors
Kiran Matcha, Johnson & Johnson Innovative Medicine, Belgium
- 10.20
- Refreshment break and exhibition
CHAIRPERSON: Robert Walton, Pfizer, UK
- 10.50
- The Applications of X-Ray Fluorescence across Chemical Process Development in the Pharmaceutical Industry
Chloe Markham, GlaxoSmithKliine, UK
- 11.30
- Nitrosamines, the journey so far
Dr Gair Ford, AstraZeneca, UK
- 12.10
- Lunch and exhibition
- 13.10
- Resolution of racemates: From classical to contemporary
Dr Michel Leeman, Symeres, The Netherlands
- 13.50
- Unexpected axial chirality behaviour: Thinking outside the box for the improvement of Lartesertib synthesis
Nunzia Langella, Merck, Italy
- 14.30
- Data-driven chemistry
Prof Jonathan M. Goodman, University of Cambridge
- 15.10
- Refreshment break and exhibition
CHAIRPERSON: Matt Burns, AstraZeneca, UK
- 15.40
- Approaches to nitrosamines risk assessments and control strategies
Paula Tomlin, AstraZeneca, UK
- 16.20
- Process Chemistry Award winner 2024: Development of processes for the radiolabelling of APIs and methods for the sustainable introduction of fluorine into organic molecules
Prof Véronique Gouverneur, University of Oxford, UK
- 17.20
- Closing remarks
- 17.30
- Wine reception sponsored by Evotec (until 18.15)
- 19.00
- Symposium dinner
Friday 12 April
CHAIRPERSON: Hazmi Tajuddin, Syngenta, UK
- 09.00
- Rapid scale-up of a novel photochemical C–N oxidative coupling: capability development and pilot-plant implementation
Stanley Lai, Syngenta, Switzerland
- 09.40
- Sandwich Pfizer Chemical R&D: a Celebration of Innovation
Dr Anna Vicini, Pfizer, UK
- 10.20
- Refreshment break and exhibition
CHAIRPERSON: Richard Horan, GlaxoSmithKline, UK
- 10.50
- Conquering the challenging manufacture and analysis of lipidic palmitoyl ethanolamine prodrug ETX-018810
David Witty, Eliem and Jade Owen, Veranova
- 11.30
- Development of a scalable, sustainable, and economical route to balcinrenone
Dr Zeina Neouchy, AstraZeneca, UK
- 12.10
- Close
SCI’s Fine Chemicals Group are committed to promoting diversity and equality in the chemical sciences. We aim to identify high quality speakers for all our conferences with full inclusivity where attendees from all backgrounds are welcome. We are open to offering flexible presentation options.
Venue and Contact
Fees
Early bird- ends 30 January 2024
SCI Member - £395
Non-member - £445
SCI Member with ensuite accommodation - £640
Non-member with ensuite accommodation - £690
|
After early bird
SCI Member - £520
Non-member - £570
SCI Member with ensuite accommodation - £765
Non-member with ensuite accommodation - £815
|
Become an SCI Member and save on this and future events
See Membership Options
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process/Deadlines
Booking terms and conditions
CPD Info
SCI Members attending this meeting are able to claim CPD points.
Silver Exhibitors
Bronze Exhibitors
-
Key Organics
-
ABCR UK
-
Radleys
-
Asymchem
-
Stolichem
-
Navin Molecular
-
ChiralQuest
-
ThalesNano
-
SpiroChem
Organising committee
-
Max Espensen, SCI/Pharmaron
-
Richard Horan, SCI/GlaxoSmithKline
-
Dave Lathbury, SCI/Astute Chemical Development Ltd
-
Hazmi Tajuddin, Syngenta
-
Robert Walton, SCI/Pfizer
-
Hilmar Weinmann, Johnson & Johnson Innovative Medicine
-
Matt Burns, SCI/AstraZeneca